| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.085 | 0.09 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.072 | 0.3 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.037 | 0.5 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.022 | 0.7 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.015 | 0.8 |